Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: NAMSA, Flagship Biosciences, And Thermo Fisher

NEW YORK (360Dx) – Medical Research Organization NAMSA said this week it has launched its in vitro diagnostic development business to aid manufacturers expedite commercialization of its products. Based in Ohio, NAMSA offers its Uniquely IVD regulatory, quality, and clinical research services. Among the services the company provides are guidance on 510(k) submissions and CE marking, as well as clinical research, biostatistics, and data management, according to its website.

Flagship Biosciences this week announced the closing of a Series A funding round to advance the growth of its computational tissue image analysis technology platform and biomarker-based diagnostics and drug development services. The firm did not disclose the amount of the financing. In addition to advancing the development of its tissue image analysis software and operational workflow, Flagship said that the funds will go toward increasing its commercial footprint to drive drug development partnerships and precision medicine.

Thermo Fisher Scientific's board this week declared a quarterly cash dividend of $.17 per share, payable on Oct. 15 to shareholders of record on Sept. 17.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.